Background: Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are life-threatening reactions that cause blistering of the skin and mucous membranes. Survivors can experience long term physical and psychological complications. The 'My SJS Passport' was co-produced by the Patient and Public Involvement group and research team at the Wolfson Centre for Personalised Medicine to improve the care and experiences of survivors.
Objectives: The aim of the study was to implement the 'My SJS Passport' in a real-world setting for evaluation by those with lived experience of SJS/TEN. The objectives were to assess participant's perceptions of its acceptability and utility when used during appointments with healthcare professionals and to explore participants' perceptions of its value and potential barriers to implementation.
Methods: A proof-of-concept study to evaluate the acceptability and usability of the passport using a mixed methods approach.
Results: A questionnaire was completed by 19 (86.4%) females and 3 (13.6%) males, while 11/22 participated focus groups. Findings suggest the passport a valuable communication tool, as it acted as the 'patient's voice' and helped in validating diagnosis with healthcare professionals, family and friends.
Conclusion: The study provides the first formal evaluation of the passport and showed that the tool is acceptable, functional and of benefit to the user. Minor barriers to implementation were identified, largely due to the COVID-19 pandemic and, to a lesser extent, the passport design. There is no comparable tool in use; thus, based on these preliminary findings, it is thought that the passport has a valuable role in supporting this underserved population.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/ced/llaf088 | DOI Listing |
Clin Exp Dermatol
March 2025
Wolfson Centre for Personalised Medicine (WCPM), Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.
Background: Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are life-threatening reactions that cause blistering of the skin and mucous membranes. Survivors can experience long term physical and psychological complications. The 'My SJS Passport' was co-produced by the Patient and Public Involvement group and research team at the Wolfson Centre for Personalised Medicine to improve the care and experiences of survivors.
View Article and Find Full Text PDFAm J Hematol
March 2025
Fred Hutchinson Cancer Research Center, Seattle, Washington State, USA.
PeerJ
November 2024
Department of Physical Education, Federal University of Paraíba, João Pessoa, Paraíba, Brazil.
Circ Cardiovasc Imaging
June 2024
Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins School of Medicine, Baltimore, MD (K.J., A.C.R., E.B., O.D., R.S.B., W.S.P., M.J.B., S.P.W.).
Background: Aortic valve calcification (AVC), Lp(a) [lipoprotein(a)], and low-density lipoprotein cholesterol (LDL-C) are associated with severe aortic stenosis (AS). We aimed to determine which of these risk factors were most strongly associated with the risk of incident severe AS.
Methods: A total of 6792 participants from the MESA study (Multi-Ethnic Study of Atherosclerosis) had computed tomography-quantified AVC, Lp(a), and LDL-C values at MESA visit 1 (2000-2002).
J Hematol Oncol
April 2024
Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Bendamustine has been retrospectively shown to be an effective and safe lymphodepletion regimen prior to the anti-CD19 chimeric antigen receptor T cell (CART) products tisagenlecleucel and axicabtagene ciloleucel, as well as the anti-BCMA CART products idecabtagene vicleucel and ciltacabtagene autoleucel. However, bendamustine as lymphodepletion prior to lisocabtagene maraleucel (liso-cel), a 4-1BB co-stimulated, fixed CD4:CD8 ratio anti-CD19 CART product, has not been described yet. Thus, we studied a cohort of sequentially-treated patients with large B-cell lymphomas who received bendamustine lymphodepletion before liso-cel at the University of Pennsylvania between 5/2021 and 12/2023 (n = 31).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!